Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. SFA_Sales_Revenues_March_2024_espi.pdfSales revenues of Sopharma AD for March 2024

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 21 / 2024
Date of issue: 2024-04-22
Short name of the issuer
SOPHARMA AD
Subject
Sales revenues of Sopharma AD for March 2024
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
Sofia, Bulgaria, April 22, 2024 – According to the requirements of art. 100t of the Law on Public Offering of Sequrities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies that for March 2024 the Company recorded a decrease in sales of 24% compared to the same month of the previous year, incl. 8% decrease in domestic sales and 32% decrease in export sales, mainly due to destabilizing market dynamics on the main export destinations.
Annexes
File Description
SFA_Sales_Revenues_March_2024_espi.pdf
SFA_Sales_Revenues_March_2024_espi.pdf		 Sales revenues of Sopharma AD for March 2024

SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2024-04-22 Ognian Donev Executive Director
20240422_130513_1293581499_SFA_Sales_Revenues_March_2024_espi.pdf

Pobierz